Zobrazeno 1 - 10
of 39
pro vyhledávání: '"C L, Marsh"'
Publikováno v:
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 16(11)
This article is a review of the salient points and a future prospective based on the 2014 Organ Procurement and Transplantation Network (OPTN)/Scientific Registry of Transplant Recipients (SRTR) liver donation and transplantation data report recently
Publikováno v:
Transplantation. 73:353-357
Until recently, islet allotransplantation for type 1 diabetic patients has been largely unsuccessful. Previous pharmacologic studies of single drugs have suggested that one factor contributing to this poor success is toxicity of immunosuppressive dru
Publikováno v:
Blood Coagulation & Fibrinolysis. 11:79-88
To better understand the regulation of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) during liver transplantation, we used a computer model of the human circulatory system to simultaneously evaluate the effect of t
Publikováno v:
Transplantation. 73(3)
Until recently, islet allotransplantation for type 1 diabetic patients has been largely unsuccessful. Previous pharmacologic studies of single drugs have suggested that one factor contributing to this poor success is toxicity of immunosuppressive dru
Autor:
C L, Marsh
Publikováno v:
Journal of child and family nursing. 2(6)
Publikováno v:
The Journal of urology. 162(2)
Diabetic cystopathy comprises a spectrum of voiding dysfunction. The usual clinical manifestations are impaired bladder sensation and detrusor contractility. Diabetic cystopathy is present in as many as 43 to 85% of patients undergoing pancreas trans
Autor:
E J, Novak, C M, Blosch, J D, Perkins, C L, Davis, D, Barr, J P, McVicar, R S, Griffin, A L, Farrand, M, Wener, C L, Marsh
Publikováno v:
Transplantation. 66(12)
Initial doses of OKT3 are associated with a cytokine-induced acute clinical syndrome (ACS). This study assessed the safety of a recombinant human tumor necrosis factor receptor fusion protein (TNFR:Fc) given to minimize OKT3-ACS symptoms in renal all
Autor:
M D, Pescovitz, G, Barone, M G, Choc, D E, Hricik, D S, Hwang, J H, Jin, J B, Klein, C L, Marsh, D I, Min, R, Pollak, T L, Pruett, J B, Stinson, J S, Thompson, E, Vasquez, T, Waid, D G, Wombolt, R L, Wong
Publikováno v:
Transplantation. 63(5)
The new microemulsion formulation of cyclosporine (CsA-ME) is more bioavailable than cyclosporine (CsA) in de novo renal transplant patients. Therefore, it was of interest to compare the safety profile of each formulation in such patients.In a multic
Autor:
G, Barone, C M, Bunke, M G, Choc, D E, Hricik, J H, Jin, J B, Klein, C L, Marsh, D I, Min, M D, Pescovitz, R, Pollak, T L, Pruett, J B, Stinson, J S, Thompson, E, Vasquez, T, Waid, D G, Wombolt, R L, Wong
Publikováno v:
Transplantation proceedings. 28(4)
Autor:
G, Barone, C T, Chang, M G, Choc, J B, Klein, C L, Marsh, J A, Meligeni, D I, Min, M D, Pescovitz, R, Pollak, T L, Pruett, J B, Stinson, J S, Thompson, E, Vasquez, T, Waid, D G, Wombolt, R L, Wong
Publikováno v:
Transplantation. 61(6)
This study was a randomized, double-blind, 12-week comparison of the pharmacokinetics, safety, and tolerability of two cyclosporine (CsA) formulations, cyclosporine emulsion capsules and oral solution for microemulsion and cyclosporine, in the postop